hCAIX-IN-23
Product Specifications
UNSPSC Description
hCAIX-IN-23 (Compound 27) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 10.4 and 8.5 nM for hCA IX and hCA XII, respectively. In addition to inhibiting hCA activity, hCAIX-IN-23 releases NO, exhibiting dual antitumor activity. hCAIX-IN-23 induces apoptosis by regulating mitochondrial caspase activity and the ferroptosis pathway (ferroptosis) through the downregulation of hCA IX and iron-regulatory protein expression. hCAIX-IN-23 is useful for renal cancer research[1].
Target Antigen
Apoptosis; Carbonic Anhydrase; Caspase; Ferroptosis; Mitochondrial Metabolism; Reactive Oxygen Species
Type
Reference compound
Related Pathways
Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hcaix-in-23.html
Smiles
O=C(N(CCC1=CC=C(C=C1)S(=O)(N)=O)CC2=CC=CC=C2)C3=CC4=NO[N+]([O-])=C4C=C3
Molecular Weight
452.48
References & Citations
[1]Bua S, et al. Harnessing Nitric Oxide-Donating Benzofuroxans for Targeted Inhibition of Carbonic Anhydrase IX in Cancer. J Med Chem. 2024 Sep 12;67(17):15892-15907.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-168030/hCAIX-IN-23-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-168030/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items